FDA expands approved use of Stivarga to treat liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm

Source: Food and Drug Administration - April 27, 2017 Category: American Health Source Type: news